Taking stock of the drug industry, from the lab to the medicine chestJanuary 5, 2026Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Chip Somodevilla/Getty Images With political savvy and outrage over drug prices, advocate David Mitchell was ahead of his time Mitchell created Patients for Affordable Drugs to raise awareness of the increasingly dire circumstances confronting many Americans. By Ed Silverman Federal health officials slash recommended childhood vaccinations under Trump's directive List of recommended shots drops from 17 to 11. New CDC guidelines follow a Trump order to align vaccine policy with peer nations. By Chelsea Cirruzzo and Helen Branswell STAT+ | A biotech incubator in China tries to unlock innovation — alongside drugmakers worldwide The incubator, founded by PC Zhu, believes it can allow researchers to test drug development ideas faster than in other countries, and at lower cost. By Brian Yang Christine Kao/STAT STAT+ | 3 issues to watch in biopharma in 2026 Biopharma issues to watch in 2026 include new obesity pills, drug patent protections, and a government drug discount program known as 340B. By Ed Silverman and Elaine Chen STAT+ | Argenx CEO to step down in May, be succeeded by COO Tim Van Hauwermeiren, who cofounded the Belgian drugmaker, has been CEO since 2008. Replacing him is Karen Massey. By Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2026, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments